Barclays lowers Arcturus Therapeutics Holdings Inc (ARCT) rating to Equal Weight and sets price target at $46

Barclays took its Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)‎ rating to the equivalent of Equal ‎Weight from Overweight, and the price target to $46,‎ ‎in a research note ‎dated December 29, 2020. ‎Other ‎analysts also revised their coverage, with ROTH Capital’s analysts downgrading the shares from ‎‎”a Buy” ‎rating to “a Sell” rating in a research note to investors issued in late December. Meanwhile, B. ‎Riley ‎Securities had maintained its rating on ARCT to the earlier “Buy” rating, in a research note ‎produced for ‎clients December 08, 2020. In addition, there was no change from B. Riley Securities on ‎December 07, ‎‎2020. The rater maintained ARCT to “a Buy” but assigned new target price of $111.

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

Is Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] a Good Buy Right Now?

It should ‎be ‎noted that ARCT technical indicators for short, intermediate as well as long term progress have ‎placed ‎an overall average of 88% as Buy. The average signal changed from 100% Buy in the last week ‎and ‎compares with 88% Buy in the past month. Data from Arcturus Therapeutics Holdings Inc.’s ‎Trend ‎Spotter indicated that the signals were Weakest. The stock current average is 1.65 million shares ‎in the ‎past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the ‎average ‎trading volume was 1.16 million shares while the medium term average advocated for 100% ‎Buy. The ‎average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.92 ‎million ‎shares.‎‎

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

ARCT Price Performance

On Wall Street, Arcturus Therapeutics Holdings ‎Inc. ‎‎[NASDAQ:ARCT] finished Monday’s session down -5.82% at $92.42. The stock went up to $103.00 ‎at ‎the same session while its lowest single day price was $92.125. In the last five days, it saw a fall ‎of ‎about -6.92%, Arcturus Therapeutics Holdings Inc. shares gained by almost 750.23% since the ‎beginning ‎of the year. However, the share price has dropped to as low as -28.75% below its one year ‎high. On ‎‎12/07/20, the company shares recorded $129.71, the highest single-day price it has got to in ‎the last 52-‎weeks and a 52-week low was seen on 03/13/20, the same year at $8.51. The company’s ‎shares have ‎inclined by 706.46% in the past year. The 50-day SMA achieved is $73.07 while the 200-day ‎SMA is ‎‎$48.59. Volume gained to 1.82 million from 1.56 million in the previous session.‎‎

ARCT Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing ‎is ‎perceived around 88.70 level, and in case of violation of this particular level, it will cause more drop ‎to ‎‎84.97 level. On the upper level, 106.72 is still the key resistance. The stock may increase to ‎the ‎subsequent resistance at 99.57. The Relative Strength Index (RSI) pinned on the 14-day chart is ‎‎50.23, ‎implying a neutral technical stance while the MACD stands at -5.87, meaning price will decrease ‎in the ‎next trading period. Percent R indicator moved to 89.97%, implying bearish price ‎movement. ‎Stochastic %K at 18.42% suggest selling the stock.‎‎

What is the short interest in Arcturus Therapeutics Holdings Inc.?

Short interest in ‎the ‎Arcturus Therapeutics Holdings Inc. stock has surged, increasing by 0.99 million shares to total ‎‎3.7 ‎million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 4.69 million, ‎data ‎from Yahoo Finance shows. The decrease of -26.76% suggests the stock saw some decreased ‎bullish ‎sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account ‎for just ‎‎19.58% of the overall float for the stock.‎‎

Arcturus Therapeutics Holdings Inc.’s Biggest Shareholders: Who Owns Arcturus ‎Therapeutics ‎Holdings Inc. [ARCT]?

Filings by ARK Investment Management LLC showed that the ‎firm now ‎holds a total of 2,495,842 shares or roughly 10.19% of the outstanding ARCT shares. This ‎means their ‎shares have increased by 577,007 from the 2,495,842 the investor reportedly held in its ‎prior 13-F filing. ‎With the conclusion of the purchase, HealthCor Management LP updated stake is ‎worth $146,306,916. ‎Details in the latest 13F filings reveal that SSgA Funds Management, Inc. acquired ‎their 504.70% stake ‎valued at $143,168,907 while Federated Global Investment Manag added theirs at ‎‎$125,252,400. During ‎the last quarter, SSgA Funds Management, Inc. raised 1,302,232 of its shares in ‎Arcturus Therapeutics ‎Holdings Inc. while Federated Global Investment Manag bought 750,000 shares. ‎The BlackRock Fund ‎Advisors’s holdings currently number 1,032,203 shares at $95396201.26. According ‎to the firm’s last 13F ‎report, The Vanguard Group, Inc. shares in the company at filing stood at 984,328 ‎shares, roughly ‎‎$90,321,937.‎‎

ARCT Earnings Forecast For The Current Quarter

Arcturus Therapeutics Holdings Inc. ‎‎[ARCT] ‎is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus ‎estimates ‎give the company expected revenues of $2.36M and an earnings per share of -$0.89 for Dec ‎‎2020. ‎Looking further ahead, the company is expected to report revenue of $10.96M at an EPS of -‎‎$0.58 for ‎Mar 2021. The estimates represent downside of 1,821.10% and 106.50% in the company’s ‎revenue and ‎earnings per share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

ARCT Earnings Estimates For The ‎Current ‎Year

For the financial year, Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] is ‎expected to ‎bring in revenue of $9.76M. The returns are nearly $-11.03 million lower than the ‎company’s actual ‎revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it ‎at -3.1, lower ‎than that of FY19 by -$0.95. Estimates put this year’s earnings growth at -44.20%, 106.50% ‎for the next. As for sales, forecasts are for a decrease of -53.10% ‎in the current fiscal year and a further ‎‎1,821.10% over the following year.‎

Most Popular

Related posts